zPREDICTA
zPREDICTA grew patient-derived tumour tissue in three-dimensional cultures that reproduce the tumour's surroundings, so drug companies could test cancer drugs on something closer to a real tumour. It was later acquired.
Overview
zPREDICTA developed organ-specific three-dimensional culture models that reconstruct the cellular and extracellular tumour microenvironment, used by pharmaceutical customers for efficacy screening of anti-cancer compounds including immuno-oncology agents, resistance mechanism studies and off-target toxicity assessment. Its YC profile cites clinical study data correlating drug efficacy in the platform with clinical response. The YC directory marks the company as acquired; the acquirer is not recorded here because no primary source was fetched, and the original domain no longer belongs to the company.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyKnown Medicine
Shares Functional (ex vivo) drug testing, Y Combinator, Patient-derived organoids and the tag yc.
- CompanyNotable Labs
Shares Functional (ex vivo) drug testing, Y Combinator and the tag yc.
- CompanyOrigin Bio
Shares Functional (ex vivo) drug testing, Y Combinator and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.